Skip to main content
Log in

Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

To study the medical cost and probability of relapse in patients with multiple sclerosis (MS) treated with either glatiramer acetate (GA) or interferon beta-1b (IFN beta.1b).

Methods

Data were obtained from the i3 InVision Data Mart™ Database from July 2001 to June 2006. We established an “intent-totreat” (ITT) cohort (n=842) of patients diagnosed with MS who began treatment with either GA or IFN beta-1b and had continuous insurance coverage from 6 months before to 2 years after the date when they began taking the medication. We also created a “continuous use” (CU) cohort (n=418) of individuals who, in addition to the criteria listed above, used either GA or IFN beta-1b within 28 days of the end of the 2-year postperiod. Using multivariate regressions, we examined both the 2-year total average direct medical costs and the likelihood of relapse within this period associated with the use of each of these MS medications. We defined relapse as being either hospitalization with a principal diagnosis of MS or having an outpatient visit with a diagnosis of MS and then prescribed steroids within a 7-day period. All regression analyses controlled for a wide range of factors that may potentially affect outcomes.

Results

In the ITT cohort, patients who started treatment with GA had a significantly lower 2-year estimated risk of relapse (13.54% vs. 5.31%; P=0.0006). In the CU cohort, patients who used GA also had a significantly lower 2-year estimated risk of relapse (10.91% vs. 2.09%; P=0.0018), as well as significantly lower average total medical costs ($53,157 vs. $48,130; P=0.0345).

Conclusions

Results from this study indicate that users of GA have a significantly lower probability of 2-year relapse than users of IFN beta-1b. In addition, among continuous users, the 2-year total average direct medical costs are significantly lower for users of GA than for users of IFN beta-1b.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005;4:111–121.

    Article  PubMed  Google Scholar 

  2. Frohman EM. Multiple sclerosis. Med Clin North Am. 2003;87:867–897, viii–ix.

    Article  PubMed  Google Scholar 

  3. Multiple Sclerosis International Federation. About MS: what is MS? http://www.msif.org/en/about_ms/what_is_ms.html. Accessed October 6, 2008.

  4. National Multiple Sclerosis Society. About MS: who gets MS? Available at http://www.nationalmssociety.org/about-multiple-sclerosis/who-gets-ms/index.aspx. Accessed October 6, 2008.

  5. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology. 2002;58:136–138.

    PubMed  Google Scholar 

  6. Richards RG, Sampson FC, Beard SM, Tappendon P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess. 2002;6:1–73.

    PubMed  CAS  Google Scholar 

  7. Multiple Sclerosis International Federation. About MS: introduction. http://www.msif.org/en/about_ms/index.html. Accessed October 6, 2008.

  8. Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry. 2000;68:144–149.

    Article  PubMed  CAS  Google Scholar 

  9. Murphy N, Confavreux C, Haas J, et al. Quality of life in multiple sclerosis in France, Germany and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neurol Neurosurg Psychiatry. 1998;65:460–466.

    Article  PubMed  CAS  Google Scholar 

  10. Multiple Sclerosis International Federation. About MS: recognised treatment for MS. http://www.msif.org/en/about_ms/recognised_treat.html. Accessed October 6, 2008.

  11. Tullman MJ, Lublin FD, Miller AE. Immunotherapy of multiple sclerosis-current practice and future directions. J Rehab Res Dev. 2002;39:273–286.

    Google Scholar 

  12. Calabresi P. Investigating glatiramer acetate for relapsing-remitting multiple sclerosis at the double dose-is more better? Nat Clin Pract Neurol. 2007;3:540–541.

    Article  PubMed  Google Scholar 

  13. Pohlman CH, Uitdehaag BM. Drug treatment of multiple sclerosis. BMJ. 2000;321:490–494.

    Article  Google Scholar 

  14. Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifroni G, Wolinsky JS. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler. 2006;12:309–320.

    Article  PubMed  CAS  Google Scholar 

  15. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998;50:701–708.

    PubMed  CAS  Google Scholar 

  16. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995;45:1268–1276.

    PubMed  CAS  Google Scholar 

  17. Khan OA, Tselis AC, Kamholz JA, et al. A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex®), IFNβ-1b (Betaseron®), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult Scler. 2001;1:349–353.

    Google Scholar 

  18. Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments-a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxoner). Eur J Neurol. 2005;12:4259–4431.

    Google Scholar 

  19. Carra A, Onaha P, Sinay V, et al. A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur J Neurol. 2003;10:671–676.

    Article  PubMed  CAS  Google Scholar 

  20. Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother. 2001;2:1149–1165.

    Article  PubMed  CAS  Google Scholar 

  21. Davis WM. Multiple sclerosis: continuing mysteriesand current management. Drug Topics. 2000;144:93–102.

    Google Scholar 

  22. Vallittu AM, Peltoniemi J, Elovaara I, et al. The efficacy of glatiramer acetate in beta-interferonintolerant MS patients. Acta Neurol Scand. 2005;112:234–237.

    Article  PubMed  CAS  Google Scholar 

  23. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health. 2004;7:554–568.

    Article  PubMed  Google Scholar 

  24. Chilcott J, McCabe C, Tappenden P, et al. Modeling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ. 2003;326:522–525.

    Article  PubMed  Google Scholar 

  25. Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm. 2007;13:44–52.

    PubMed  Google Scholar 

  26. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of 4 immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Phar. 2007;13:245–261.

    Google Scholar 

  27. Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. Curr Opin CNS Drugs. 2004;18:561–574.

    Article  Google Scholar 

  28. Bureau of Labor Statistics. Consumer Price Index. Available at http://www.bls.gov/cpi. Accessed April 20, 2009.

  29. Ollendorf D, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8:469–476.

    PubMed  Google Scholar 

  30. Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71:129–135.

    Article  PubMed  Google Scholar 

  31. National Multiple Sclerosis Society. About MS: epidemiology of MS. Available at http://www.nationalmssociety.org/about-multiple-sclerosis/whogets-ms/epidemiology-of-ms/index.aspx. Accessed October 8, 2008.

  32. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler. 2008;14:1091–1098.

    Article  PubMed  Google Scholar 

  33. Miller A. Paroxysmal disorders. In: Burks JS, Johnson KP, eds. Multiple sclerosis: diagnosis, medical management, and rehabilitation. New York: Demos Medical Publishing, Inc.; 2000.

    Google Scholar 

  34. Pöllmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs. 2008;22:291–324.

    Article  PubMed  Google Scholar 

  35. Trouillas P, Courjon J. Epilepsy with multiple sclerosis. Epilepsia. 2007;13:325–333.

    Article  Google Scholar 

  36. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler. 2000;6:255–266.

    PubMed  CAS  Google Scholar 

  37. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45:1277–1285.

    Google Scholar 

  38. Kobelt G, Berg J, Atherley D, Hadjimichael O, Jonsson B. Costs and quality of life in multiple sclerosis: a cross-sectional study in the USA. Neurology. 2006;66:1696–1702.

    Article  PubMed  Google Scholar 

  39. Whetten-Goldenstein K, Sloan FA, Goldenstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler. 1998;4:419–425.

    Google Scholar 

  40. i3. Data assets: better data matters. http://www.i3-global.com/DataAssets. Accessed October 8, 2008.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Maureen J. Lage.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Castelli-Haley, J., Oleen-Burkey, M.A., Lage, M.J. et al. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. Adv Therapy 26, 552–562 (2009). https://doi.org/10.1007/s12325-009-0028-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-009-0028-3

Keywords

Navigation